At our clinic, a portion of the outcomes obtained through research and development in the field of immune cell therapy and related technologies has been protected as intellectual property through patent registration.
These patents are based on knowledge accumulated in clinical practice and research settings, and have been secured with the aim of improving the safety, reproducibility, and appropriate management of medical technologies and research.
The acquisition of patents does not indicate specific therapeutic efficacy or clinical outcomes, but represents one aspect of the research and academic activities conducted by our clinic.
List of Granted Patents
Proliferating Agent for Monocyte, Culture Medium for Proliferating Monocyte, Method for Producing Monocyte, Method for Producing Dendritic Cell, and Method for Producing Dendritic Cell Vaccine
This patent relates to a technology that enables efficient cultivation and utilization of monocytes from a small volume of peripheral blood without the use of apheresis.
The method aims to improve manufacturing efficiency in dendritic cell–based immunotherapy while reducing the physical burden on patients.
Japan Patent No. 5577472 (Granted: July 11, 2014)
Registered in 11 countries and regions, including the United States (US 9,303,247 B2) and Europe (EP 2749639 B1)
Method for Obtaining Monocytes or NK Cells
This patent establishes a method for simultaneously isolating and expanding monocytes and NK cells from a small volume of peripheral blood, enabling repeated immune cell therapy to be carried out continuously while minimizing patient burden.
Japan Patent No. 5856025 (Granted: December 18, 2015)
Registered in 11 countries and regions, including the United States (US 10,113,148 B2) and Europe (EP 2881462)
Method for Undifferentiated Growth of Mesenchymal Stem Cell and Method for Concentration of Mesenchymal Stem Cell
This patent establishes techniques for proliferating and concentrating mesenchymal stem cells while maintaining their undifferentiated state, with the aim of improving stability and practical applicability in regenerative medicine.
Japan Patent No. 5856029 (Granted: December 18, 2015)
Registered in 9 countries and regions, including the United States (US 9,670,461 B2) and Europe (EP 2891713)
Method for Manufacturing an Immune Cell–Containing Composition, and A Cancer-Treating Composition
This patent establishes a method for efficiently producing immune cell–containing compositions in which NK cells, NKT cells, and T cells are differentiated and expanded in a balanced manner from mononuclear cells. The technology contributes to improving the practicality of immune cell therapy while reducing patient burden.
Japan Patent No. 5997296 (Granted: September 2, 2016)
Registered in 9 countries and regions, including the United States (US 10,160,952 B2) and Europe (EP 2947144)
About Our Intellectual Property
The patents held by our clinic have been obtained against the background of accumulated basic research and clinical experience in immune cell therapy.
These technologies are reflected in our approaches to research, manufacturing, and quality control, and constitute one of the foundations supporting our current clinical practice.